Latest Strategic Development News

Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.

Centuria Industrial REIT (ASX – CIP) reported a robust HY26 with strong income growth, portfolio valuation gains, and an upgraded full-year earnings forecast, underpinned by active leasing and strategic capital management.

National Storage REIT has reported a robust half-year performance with rising earnings and a significant takeover proposal offering a 26.5% premium to shareholders.

Dexus Convenience Retail REIT has reported solid half-year results for 2026, underpinned by resilient income growth and a $19.8 million uplift in portfolio valuation. The fund maintains a conservative capital structure while advancing key development projects.

Dexus Convenience Retail REIT (DXC) reports solid HY26 results with strong income growth and high occupancy, while advancing strategic development projects to enhance its metro and highway retail footprint.

Electro Optic Systems (EOS) addresses rumours about relocating its headquarters and stock listing to Europe, affirming no such decisions have been made despite strong growth in European defence markets.

ChemX Materials Limited remains suspended from ASX trading as it finalises overdue financial reports and secures informal funding, aiming for share reinstatement.

Beacon Minerals delivered a strong December quarter with increased gold production and improved recovery rates, while progressing key mining and exploration activities at the Lady Ida Gold Project.

Chalice Mining has completed a pivotal Pre-Feasibility Study for its Gonneville Palladium-Nickel-Copper Project, defining a maiden Ore Reserve and setting sights on a Final Investment Decision by mid-2028 amid robust metal prices.

Infinity Mining confirms exceptional antimony grades at Walhalla South Extended and advances a groundbreaking extraction partnership at its Cangai Copper Project.

Experience Co Limited reports a modest half-year revenue increase despite challenges in Q2, driven by strong Reef Unlimited and Skydive New Zealand performances offsetting softness elsewhere.

Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent and is preparing for a key FDA submission, while appointing a new president to lead its US operations.